BusinessWeek Logo
November 23, 2009 9:39 AM ET
Novacea, Inc.
SnapshotPeople

Company Overview

As of January 30, 2009, Novacea, Inc. was acquired by Transcept Pharmaceuticals, Inc., in a reverse merger transaction. Novacea, Inc., a biopharmaceutical company, focuses on in-licensing, developing, and commercializing therapies for the treatment of cancer. The company’s product candidates include Asentar, which is in Phase III clinical trial for the treatment of androgen-independent prostate cancer and in Phase II clinical trial for the treatment of advanced pancreatic cancer; and AQ4N, a hypoxia-activated prodrug in Phase Ib/IIa clinical trial for the treatment of glioblastoma multiforme. It has license and collaboration agreements with Aventis Pharmaceuticals, Inc.; Oregon Health & Scie...

Detailed Description

400 Oyster Point Boulevard

Suite 200

South San Francisco, CA 94080

United States

Founded in 2001

9 Employees

Phone:

650-228-1800

Fax:

650-228-1088

Key Executives

Novacea, Inc. does not have any Key Executives recorded. If you would like to update data for this company, follow the link below and fill out the form.

Key developments for Novacea, Inc.

Novacea, Inc. expected to Report Q3 2009 Results on November 12, 2009. This event was calculated by Capital IQ (Created on November 6, 2009).
11/6/2009

Novacea, Inc. expected to Report Q3 2009 Results on November 12, 2009. This event was calculated by Capital IQ (Created on November 6, 2009).

Novacea Inc., Special/Extraordinary Shareholders Meeting, Jan 27, 2009
01/6/2009

Novacea Inc., Special/Extraordinary Shareholders Meeting, Jan 27, 2009, at 09:00 US Pacific Time. Location: 400 Oyster Point Boulevard, Suite 200, South San Francisco, CA 94080, United States. Agenda: To approve the proposed merger between Novacea and Transcept Pharmaceuticals Inc.

Novacea Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2008
11/10/2008

Novacea Inc. reported earnings results for the third quarter and nine months ended September 30, 2008. For the quarter, the company reported net loss of $6.9 million, or $0.27 per share as compared to net loss of $3.2 million, or $0.13 loss per share for the third quarter of 2007. Collaboration revenue was $93,000 as compared to $8,566,000 for the same period last year. For nine months, the company reported net income of $39.1 million, or $1.51 per share as compared to a net loss of $29.9 million, or $1.26 loss per share for the nine months ended September 30, 2007. Collaboration revenue was $60,621,000 as compared to $8,702,000 for the same period last year.

Similar Private Companies By Industry

Company Name Region
EcoChoice Protein Corporation United States
MicroDose Therapeutx, Inc. United States
Mirna Therapeutics, Inc. United States
CMIC-VPS Corporation United States
Innocoll, Inc. United States

Recent Private Companies Transactions

Type
Date		 Target
No transactions available in the past 12 months.


Stock Quotes

Company Lookup
Recently Viewed
NTG (GB) 248.60 GBX +1.60
VVC $23.32 USD 0.00
PALM $11.74 USD 0.00
TXT $19.64 USD 0.00
XNS1V (FI) €2.99 EUR +0.05

Market data is delayed at least 20 minutes.

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States
Mccombs School Of Business At The University Of Texas At Austin United States

Companies Toolbox

Company Tools
Report Error Update/report
content errors
Submit private company Submit private company
Upload your company video Upload your company video
Investing Tools
Newsletter Newsletter
Blogs Blogs
RSS feed RSS feeds
Podcasts Podcasts
Videos Videos



Close Recommend A Data Enhancement Or Correction

For Novacea, Inc. Private

Submitting this data update / error report instantly puts the correct information in the hands of our researcher, who will investigate your report and, if necessary, make the changes to the company profile. Be sure to fill out the form completely.

Required Information Missing - Please enter your information in the following field(s):
DATA TO BE REVIEWED
Page Section*

Please indicate in which section the error appears. Section headers are in light gray type at the top of each CIC page module.

Data Point*

Please indicate which data is in error.

CONTACT INFORMATION

Please provide your name and email address in case our researchers need to get in touch with you as they investigate the error.

Your Name*
Your E-Mail Address*
YOUR RECOMMENDATION

Describe why you feel the data point is incorrect and indicate sources our researchers should check when they investigate the error.

Cancel Submit
You can drag this form within your browser window.

Thank you for submitting your information. We investigate data update requests and error reports as quickly as possible. Since some are easier to investigate than others, please be patient as we perform our research; it could take several weeks, depending on the nature of the error and whether your company is public or private.

You can drag this form within your browser window.